IN BRIEF: Novacyt launches two new PCR tests amid lateral flow delays

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Launches two new ...

Alliance News 1 October, 2021 | 7:28AM
Email Form Facebook Twitter LinkedIn RSS

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Launches two new CE marked PCR tests. One test, Winterplex, can diagnose Covid-19, types of influenza and respiratory syncytial virus, which can cause infections of the respiratory tract. Another test, named Escapeplex, can diagnose four Covid-19 variants. However, company notes an already announced delay to its PathFlow lateral flow test is down to increased demand for self-test approvals, leading to regulatory backlog. "The notified body has communicated a delay of up to six months, therefore, the company is also evaluating other approved options for a Covid-19 self-LFT," Novacyt says.

Current stock price: 277.10 pence, down 3.3% on Thursday

Year-to-date change: down 68%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Novacyt SA 4.03 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.